Claims:

A complete list of all claims under examination is set out below. Please cancel claims 1-10, 21, 23-25; 29, 30, 32 and 33; amend claims 11, 16, 19, 20, 22, 26-28 and 31, and add claims 34-43 as follows:

1 – 10. (Cancelled)

11. (Amended) The compound of claim 34 ~~claim 1 wherein the compound is~~ represented by the formula:



wherein

R_{11} is selected from the group consisting of C_5-C_{12} alkyl, C_5-C_{12} alkoxy, C_5-C_{12} alkenyl, and C_5-C_{12} alkynyl;

R_7 and R_8 are independently selected from the group consisting of O, S, CHR_{26}, CHR_{26}, NR_{26}, and N;

wherein R_{26} is H, F or C_1-C_4 alkyl;

R_{25} is N or CH;

R_2 is NH_2;

R_3 is selected from the group consisting of H, C_1-C_4 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



PAGE 4/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

BEST AVAILABLE COPY

wherein X and R_{12} are independently ~~is~~ selected from the group consisting of O and S;

R_{23} is selected from the group consisting of H, F, OH, C_1-C_4 alkyl, CO_2H and C_1-C_4 alkyl;

R_{24} is selected from the group consisting of H, F, C_1-C_4 alkyl and PO_3H_2, or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group; and

y and m are integers independently ranging from 0 to 4;

or a pharmaceutically acceptable salt or tautomer thereof.

12. (Original) The compound of claim 11 wherein

m is 0;

y is 0 or 1;

R_{25} is CH;

R_{23} is H or F; and

R_{24} is selected from the group consisting of H, F and C_1-C_4 alkyl.

13. (Original) The compound of claim 11 wherein R_3 is selected from the group consisting of C_1-C_3 alkyl and (C_1-C_4 alkyl)OH.

14. (Original) The compound of claim 12 or 13 wherein

R_7 is NH; and

X is O;

or a pharmaceutically acceptable salt or tautomer thereof.

15. (Original) The compound of claim 14 wherein

y is 0; and

R_{15} is OH.

PAGE 5/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

16. (Amended) The compound of claim 13 ~~wherein the compound is~~ represented by the formula:



or



wherein R_{11} is C_5-C_{18} alkyl, C_5-C_{12} alkoxy, or C_5-C_{18} alkenyl; and

R_8 is N;

or a pharmaceutically acceptable salt or tautomer thereof.

17. (Original) The compound of claim 16 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S;

or a pharmaceutically acceptable salt or tautomer thereof.

18. (Original) The compound of claim 17 wherein R_{11} is C_5-C_9 alkyl;

R_{15} is OH and

PAGE 6/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

R_3 is selected from the group consisting of CH_3, CH_2CH_3, CH_2OH, CH_2CH_2OH and $CH_2CH_2CH_2OH$.

19. (Amended) A composition comprising a compound of claim [[1, 2, 6, 8]] 34, 11 or 16 and a pharmaceutically acceptable carrier.

20. (Amended) A pharmaceutical composition comprising a compound represented by the formula:



wherein R_{11} is C_5-C_{18} alkyl C_5-C_{12} alkoxy or C_5-C_{18} alkenyl;

Q is selected from the group consisting of C_3-C_6 optionally substituted cycloalkyl, C_3-C_6 optionally substituted heterocyclic, C_3-C_6 optionally substituted aryl, C_3-C_6 optionally substituted heteroaryl and -NH(CO)-;

[[R_2]] R_3 is selected from the group consisting of H, C_1-C_4 alkyl and (C_1-C_4 alkyl)OH;

R_{23} is H or C_1-C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein X and R_{12} are independently ~~is~~ selected from the group consisting of O and S;

or a pharmaceutically acceptable salt or tautomer thereof and

a pharmaceutically acceptable carrier.

21. (Cancelled)

22. (Amended) The composition of claim [[21]] 38 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

23. - 25. (Cancelled)

26. (Amended) The method of claim 36 ~~claim 25~~ further comprising the step of administering a second immuno-modulatory agent selected from the group consisting of cyclosporine, tacrolimus, rapamycin, azathioprine, and corticosteroids ~~such as prednisolone and prednisone~~.

27. (Amended) The method of claim 36 ~~claim 25~~ wherein the compound has the general formula:



wherein R_{11} is selected from the group consisting of C_1-C_{22} alkyl, C_5-C_{12} alkoxy, C_2-C_{22} alkenyl and C_2-C_{22} alkynyl;

R_3 is selected from the group consisting of NH_2, OH, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, -(C_1-C_4 alkyl)NH_2, (C_1-C_4 alkyl)aryl(C_0-C_4 alkyl) and (C_1-C_4 alkyl)aryloxyaryl(C_0-C_4 alkyl);

R_8 is selected from the group consisting of O, S and N.

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein R_{12} is selected from the group consisting of O, NH and S; and

X is selected from the group consisting of O, NH and S; or a pharmaceutically acceptable salt or tautomer thereof.

28. (Amended) A method of promoting wound healing in a warm blooded vertebrate, said method comprising the step of administering a composition comprising a [[a]] compound of the general structure:





wherein R_{11} is C_5-C_{18} alkyl, C_5-C_{12} alkoxy, or C_5-C_{18} alkenyl;

Q is selected from the group consisting of C_3-C_6 optionally substituted cycloalkyl, C_3-C_6 optionally substituted heterocyclic, C_3-C_6 optionally substituted aryl, C_3-C_6 optionally substituted heteroaryl and -NH(CO)-;

[[R_2]] R_3 is selected from the group consisting of H, C_1-C_4 alkyl and (C_1-C_4 alkyl)OH;

R_{23} is H or C_1-C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein X and R_{12} are independently ~~is~~ selected from the group consisting of O and S;

or a pharmaceutically acceptable salt or tautomer thereof.

29. (Cancelled)

30. (Cancelled)

31. (Amended) A method for treating a patient suffering from a disease associated with abnormal cell growth, said method comprising the steps of administering a [[a]] compound of the general structure:



PAGE 10/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

wherein R_{11} is located in the meta or para position and is selected from the group consisting of C_5-C_{18} alkyl and C_5-C_{18} alkenyl;

Q is selected from the group consisting of C_3-C_6 optionally substituted cycloalkyl, C_3-C_6 optionally substituted heterocyclic, C_3-C_6 optionally substituted aryl C_3-C_6 optionally substituted heteroaryl and -NH(CO)-;

R_3 [[R_2]] is selected from the group consisting of H, C_1-C_4 alkyl and (C_1-C_4 alkyl)OH;

R_{23} is H or C_1-C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein X and R_{12} are independently is selected from the group consisting of O and S;

or a pharmaceutically acceptable salt or tautomer thereof.

32. (Cancelled)

33. (Cancelled)

34. (New) A compound represented by the formula:



wherein

PAGE 11/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

R_{11} is selected from the group consisting of C_5-C_{12} alkyl, C_5-C_{12} alkenyl, C_5-C_{12} alkynyl, C_5-C_{12} alkoxy, $(CH_2)_pO(CH_2)_q$, C_5-C_{10} (aryl)R_{20}, C_5-C_{10} (heteroaryl)R_{20}, C_5-C_{10} (cycloalkyl)R_{20}, C_5-C_{10} alkoxy(aryl)R_{20}, C_5-C_{10} alkoxy(heteroaryl)R_{20} and C_5-C_{10} alkoxy(cycloalkyl)R_{20};

wherein R_{20} is H or C_1-C_{10} alkyl;

R_{29} is H or halo;

R_2 is NH_2;

R_3 is selected from the group consisting of H, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{23} is selected from the group consisting of H, F, NH_2, OH, CO_2H, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{24} is selected from the group consisting of H, F and PO_3H_2, or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group;

R_{25}, R_7, and R_8 are independently selected from the group consisting of O, S, CHR_{26}, CR_{26}, NR_{26}, and N;

wherein R_{26} is H, F or C_1-C_4 alkyl;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



;

wherein R_{12} is selected from the group consisting of O, NH and S;

X is selected from the group consisting of O, NH and S;

y and m are integers independently ranging from 0 to 4;

p and q are integers independently ranging from 1 to 10;

or a pharmaceutically acceptable salt or tautomer thereof.

35. (New) A method for modulating the activity of an S1P receptor, said method comprising contacting said receptor with a compound represented by the formula:

PAGE 12/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36



wherein

R_{11} is selected from the group consisting of C_1-C_{12} alkyl, C_2-C_{12} alkenyl, C_2-C_{12} alkynyl, C_5-C_{12} alkoxy, $(CH_2)_pO(CH_2)_q$, C_5-C_{10} (aryl)R_{20}, C_5-C_{10} (heteroaryl)R_{20}, C_5-C_{10} (cycloalkyl)R_{20}, C_5-C_{10} alkoxy(aryl)R_{20}, C_5-C_{10} alkoxy(heteroaryl)R_{20} and C_5-C_{10} alkoxy(cycloalkyl)R_{20};

wherein R_{20} is H or C_1-C_{10} alkyl;

R_{29} is H or halo;

R_2 is NH_2;

R_3 is selected from the group consisting of H, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{23} is selected from the group consisting of H, F, CO_2H, OH, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{24} is selected from the group consisting of H, F and PO_3H_2, or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group;

R_{25}, R_7 and R_8 are independently selected from the group consisting of O, S, CHR_{26}, CR_{26}, NR_{26}, and N;

wherein R_{26} is H, F or C_1-C_4 alkyl;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein R_{12} is selected from the group consisting of O, NH and S;

X is selected from the group consisting of O, NH and S;

y and m are integers independently ranging from 0 to 4;

p and q are integers independently ranging from 1 to 10;

or a pharmaceutically acceptable salt or tautomer thereof.

36. (New) A method of providing immuno-modulation to a patient in need thereof, said method comprising the step of administering to said patient a composition comprising a compound represented by the formula:



wherein

R_{11} is selected from the group consisting of C_1-C_{18} alkyl, C_2-C_{18} alkenyl, C_2-C_{18} alkynyl, C_5-C_{18} alkoxy, $(CH_2)_pO(CH_2)_q$, C_5-C_{10} (aryl)R_{20}, C_5-C_{10} (heteroaryl)R_{20}, C_5-C_{10} (cycloalkyl)R_{20}, C_5-C_{10} alkoxy(aryl)R_{20}, C_5-C_{10} alkoxy(heteroaryl)R_{20} and C_5-C_{10} alkoxy(cycloalkyl)R_{20};

wherein R_{20} is H or C_1-C_{10} alkyl;

R_{29} is H or halo;

R_2 is NH_2;

R_3 is selected from the group consisting of H, C_1-C_6 alkyl, (C_1-C_4 alkyl)OH, and (C_1-C_4 alkyl)NH_2;

R_{24} is selected from the group consisting of H, F and PO_3H_2, or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group;

R_{25}, R_7 and R_8 are independently selected from the group consisting of O, S, CHR_{26}, CR_{26}, NR_{26}, and N;

wherein R_{26} is H, F or C_1-C_4 alkyl;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein R_{12} is selected from the group consisting of O, NH and S;

PAGE 14/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

X is selected from the group consisting of O, NH and S;
y and m are integers independently ranging from 0 to 4;
p and q are integers independently ranging from 1 to 10;
or a pharmaceutically acceptable salt or tautomer thereof.

37. (New) The method of claim 26 wherein the corticosteroids is prednisolone or prednisone.

38. (New) The composition of claim 20 wherein Q is selected from the group consisting of



39. (New) The composition of claim 22 wherein Q is selected from the group consisting of


, and

R_{15} is OH;
or a pharmaceutically acceptable salt or tautomer thereof.

40. (New) The method of claim 28 wherein Q is selected from the group consisting of -NH(CO)-,

PAGE 15/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36



and R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

41. (New) The method of claim 40 wherein Q is selected from the group consisting of



, and

R_{15} is OH;

or a pharmaceutically acceptable salt or tautomer thereof.

42. (New) The method of claim 31 wherein Q is selected from the group consisting of -NH(CO)-;

PAGE 16/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36



and R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

43. (New) The method of claim 42 wherein

Q is selected from the group consisting of



, and

R_{15} is OH;

or a pharmaceutically acceptable salt or tautomer thereof.

PAGE 17/20 * RCVD AT 9/14/2006 7:09:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/20 * DNIS:2738300 * CSID:612 331 7401 * DURATION (mm-ss):02-36

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☑ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.